Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

[1]  M. Leppert,et al.  Polymorphisms in the Nonmuscle Myosin Heavy Chain 9 Gene (MYH9) Are Associated with Albuminuria in Hypertensive African Americans: The HyperGEN Study , 2009, American Journal of Nephrology.

[2]  D. Reich,et al.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.

[3]  D. Vlahov,et al.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.

[4]  Keith C. Norris,et al.  Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. , 2008, Archives of internal medicine.

[5]  C. Langefeld,et al.  Association of the Distal Region of the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Gene With Type 2 Diabetes in an African-American Population Enriched for Nephropathy , 2008, Diabetes.

[6]  K. Asanuma,et al.  Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. , 2007, Trends in cell biology.

[7]  M. Winn,et al.  TRPC6 and FSGS: the latest TRP channelopathy. , 2007, Biochimica et biophysica acta.

[8]  B. Freedman,et al.  Familial Clustering of Chronic Kidney Disease , 2007, Seminars in dialysis.

[9]  M. Kelley,et al.  Genotype–phenotype correlation in MYH9‐related thrombocytopenia , 2005, British journal of haematology.

[10]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[11]  D. Bowden,et al.  Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease. , 2005, Kidney international.

[12]  Hua Tang,et al.  Estimation of individual admixture: Analytical and study design considerations , 2005, Genetic epidemiology.

[13]  G. Abecasis,et al.  A note on exact tests of Hardy-Weinberg equilibrium. , 2005, American journal of human genetics.

[14]  D. Vlahov,et al.  Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. , 2005, Physiological genomics.

[15]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[16]  Scott M. Williams,et al.  A high-density admixture map for disease gene discovery in african americans. , 2004, American journal of human genetics.

[17]  C. Marcantoni,et al.  Hypertensive nephrosclerosis in African Americans versus Caucasians. , 2002, Kidney international.

[18]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[19]  S. Iyengar,et al.  Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  J. Kaplan,et al.  Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis , 2000, Nature Genetics.

[21]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[22]  B. Freedman,et al.  The link between hypertension and nephrosclerosis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  J. Curtis,et al.  Clinical documentation of end-stage renal disease due to hypertension. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  B. Freedman,et al.  The familial risk of end-stage renal disease in African Americans. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  R. Neuwirth,et al.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. , 1992, JAMA.

[26]  M. Blaufox,et al.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. , 1989, Hypertension.

[27]  H. Dustan,et al.  Renal insufficiency in treated essential hypertension. , 1989, The New England journal of medicine.

[28]  W. McClellan,et al.  Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  J. Breyer,et al.  Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. , 1997, Kidney international.

[30]  B. Freedman,et al.  Renal biopsy findings in presumed hypertensive nephrosclerosis. , 1994, American journal of nephrology.